| 1.28 0.08 (6.67%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.64  |
1-year : | 1.84 |
| Resists | First : | 1.41 |
Second : | 1.58 |
| Pivot price | 1.23 |
|||
| Supports | First : | 1.13 | Second : | 0.94 |
| MAs | MA(5) : | 1.23 |
MA(20) : | 1.24 |
| MA(100) : | 1.26 |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46 |
D(3) : | 40.2 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 2.23 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CODX ] has closed below upper band by 22.6%. Bollinger Bands are 60.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.28 - 1.29 | 1.29 - 1.29 |
| Low: | 1.2 - 1.2 | 1.2 - 1.21 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Wed, 02 Oct 2024
Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3 - StockTitan
Wed, 02 Oct 2024
Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3 - PR Newswire
Tue, 24 Sep 2024
Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan - PR Newswire
Thu, 05 Sep 2024
Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test - PR Newswire
Thu, 15 Aug 2024
Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C. - PR Newswire
Thu, 08 Aug 2024
Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3.019e+007 (%) |
| Held by Institutions | 5.4 (%) |
| Shares Short | 301 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.742e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -289.1 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -42.8 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 5.87 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 225780 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|